OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Therapeutic cancer vaccines: a long and winding road to success
Constantin N. Baxevanis, Michael Papamichail, Sonia A. Perez
Expert Review of Vaccines (2013) Vol. 13, Iss. 1, pp. 131-144
Closed Access | Times Cited: 13
Constantin N. Baxevanis, Michael Papamichail, Sonia A. Perez
Expert Review of Vaccines (2013) Vol. 13, Iss. 1, pp. 131-144
Closed Access | Times Cited: 13
Showing 13 citing articles:
Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities
Colby S. Shemesh, Joy Hsu, Iraj Hosseini, et al.
Molecular Therapy (2020) Vol. 29, Iss. 2, pp. 555-570
Open Access | Times Cited: 204
Colby S. Shemesh, Joy Hsu, Iraj Hosseini, et al.
Molecular Therapy (2020) Vol. 29, Iss. 2, pp. 555-570
Open Access | Times Cited: 204
The Role of Therapeutic Vaccines in Cancer Immunotherapy
Constantin N. Baxevanis, Ourania E. Tsitsilonis, Maria Goulielmaki, et al.
Onco (2025) Vol. 5, Iss. 1, pp. 11-11
Open Access
Constantin N. Baxevanis, Ourania E. Tsitsilonis, Maria Goulielmaki, et al.
Onco (2025) Vol. 5, Iss. 1, pp. 11-11
Open Access
Glycobiology of Neuroblastoma: Impact on Tumor Behavior, Prognosis, and Therapeutic Strategies
Nora Berois, Eduardo Osinaga
Frontiers in Oncology (2014) Vol. 4
Open Access | Times Cited: 39
Nora Berois, Eduardo Osinaga
Frontiers in Oncology (2014) Vol. 4
Open Access | Times Cited: 39
T cell receptor mimic antibodies for cancer therapy
Leonid Dubrovsky, Tao Dao, Ron S. Gejman, et al.
OncoImmunology (2015) Vol. 5, Iss. 1, pp. e1049803-e1049803
Open Access | Times Cited: 38
Leonid Dubrovsky, Tao Dao, Ron S. Gejman, et al.
OncoImmunology (2015) Vol. 5, Iss. 1, pp. e1049803-e1049803
Open Access | Times Cited: 38
Diaminosulfide based polymer microparticles as cancer vaccine delivery systems
Sean M. Geary, Qiaohong Hu, Vijaya B. Joshi, et al.
Journal of Controlled Release (2015) Vol. 220, pp. 682-690
Open Access | Times Cited: 28
Sean M. Geary, Qiaohong Hu, Vijaya B. Joshi, et al.
Journal of Controlled Release (2015) Vol. 220, pp. 682-690
Open Access | Times Cited: 28
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit
Eleftheria A. Anastasopoulou, Ioannis F. Voutsas, Theodora Keramitsoglou, et al.
Cancer Immunology Immunotherapy (2015) Vol. 64, Iss. 9, pp. 1123-1136
Open Access | Times Cited: 17
Eleftheria A. Anastasopoulou, Ioannis F. Voutsas, Theodora Keramitsoglou, et al.
Cancer Immunology Immunotherapy (2015) Vol. 64, Iss. 9, pp. 1123-1136
Open Access | Times Cited: 17
Can calcium signaling be harnessed for cancer immunotherapy?
Ronald Rooke
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2014) Vol. 1843, Iss. 10, pp. 2334-2340
Closed Access | Times Cited: 10
Ronald Rooke
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2014) Vol. 1843, Iss. 10, pp. 2334-2340
Closed Access | Times Cited: 10
Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design
Constantin N. Baxevanis, Sotirios P. Fortis, Alexandros Ardavanis, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 2908-2908
Open Access | Times Cited: 10
Constantin N. Baxevanis, Sotirios P. Fortis, Alexandros Ardavanis, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 2908-2908
Open Access | Times Cited: 10
HER2-Specific Vaccines for HER2-Positive Breast Cancer Immunotherapy
Maxwell Omabe, Shahid Ahmed, Amer Sami, et al.
World Journal of Vaccines (2015) Vol. 05, Iss. 02, pp. 106-128
Open Access | Times Cited: 6
Maxwell Omabe, Shahid Ahmed, Amer Sami, et al.
World Journal of Vaccines (2015) Vol. 05, Iss. 02, pp. 106-128
Open Access | Times Cited: 6
Novel fusion cells derived from tumor cells expressing the heterologous α-galactose epitope and dendritic cells effectively target cancer
Fengzhen Mo, Dabing Xue, Siliang Duan, et al.
Vaccine (2019) Vol. 37, Iss. 7, pp. 926-936
Closed Access | Times Cited: 5
Fengzhen Mo, Dabing Xue, Siliang Duan, et al.
Vaccine (2019) Vol. 37, Iss. 7, pp. 926-936
Closed Access | Times Cited: 5
Immunologic biomarkers in prostate cancer
Constantin N. Baxevanis, Michael Papamichail, Sonia A. Perez
Human Vaccines & Immunotherapeutics (2014) Vol. 10, Iss. 5, pp. 1244-1247
Open Access | Times Cited: 4
Constantin N. Baxevanis, Michael Papamichail, Sonia A. Perez
Human Vaccines & Immunotherapeutics (2014) Vol. 10, Iss. 5, pp. 1244-1247
Open Access | Times Cited: 4
Dendritic Cells as Targets of Vaccines and Adjuvants
Marius Strioga, Neringa Dobrovolskienė
Elsevier eBooks (2017), pp. 43-64
Closed Access | Times Cited: 1
Marius Strioga, Neringa Dobrovolskienė
Elsevier eBooks (2017), pp. 43-64
Closed Access | Times Cited: 1
Low-Dose Chemomodulation and Cancer Vaccines
Anton А. Keskinov
Journal of Vaccines & Vaccination (2014) Vol. 05, Iss. 01
Open Access
Anton А. Keskinov
Journal of Vaccines & Vaccination (2014) Vol. 05, Iss. 01
Open Access
